Febuxostat, a novel, orally administered, potent, non–purine analogue, xanthine oxidase inhibitor in the management of hyperuricemia in patients with gout & chronic tophaceous gout. It has minimal effects on other enzymes involved in purine and pyrimidine metabolism, and is metabolized mainly by glucuronide formation and oxidation in the liver. In a study of subjects with renal impairment, the serum urate–lowering effect of febuxostat was unaltered. Febuxostat, at a daily dose of 80 mg or 120 mg, was more effective than allopurinol at the commonly used fixed daily dose of 300 mg in lowering serum urate.
The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
We use cookies and other tracking technologies to work properly, to analyze our website traffic, and to understand where our visitors are coming from. More InfoGot It!
